Evogene (EVGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.70M
Last updated: Nov 17, 2026 at 11:05 AM ET
Evogene (EVGN) Stock Forecast
Analysts expect Evogene (EVGN) to earn -$1.10 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.44M. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.60.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 80.6%.
- Fiscal year ending Dec 31, 2026
- -$1.10
- EPS consensus, revenue $1.44M
- Fiscal year ending Dec 31, 2027
- -$0.60
- EPS consensus, revenue $2.60M
- Next report
- Nov 19, 2026
- Confirmed, before the open
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.10 | -$1.10 to -$1.10 | 1 | $1.44M | $1.44M to $1.44M | 1 |
| Dec 31, 2027 | -$0.60 | -$0.60 to -$0.60 | 1 | $2.60M | $2.60M to $2.60M | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | N/A | 3 | $397800 | $382200 to $409500 | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.70.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.10 | -$1.70 | -$1.70 | -$1.70 | -$1.70 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.60 | -$0.80 | -$0.80 | -$0.80 | -$0.80 | N/A |
Frequently Asked Questions About EVGN
What is the EVGN stock forecast?
Consensus analyst estimates put Evogene's EPS at -$1.10 for the fiscal year ending Dec 31, 2026, on revenue of $1.44M.
What EPS do analysts expect from EVGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.10, with estimates from -$1.10 to -$1.10 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.60, with estimates from -$0.60 to -$0.60 from 1 analyst.
What revenue do analysts expect from Evogene next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.44M, with estimates from $1.44M to $1.44M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.60M, with estimates from $2.60M to $2.60M.
How many analysts cover EVGN?
1 analyst estimates EPS for Evogene for the fiscal year ending Dec 31, 2026.
EVGN pages: Overview, Earnings, Forecast, Financials, Competitors